Document:

<PAGE>

                                                                    Exhibit 10.1

                              EMPLOYMENT AGREEMENT

         This Employment Agreement (the "Agreement"), is made and entered into
this 26th day of December, 2001, by and between Innovative Drug Delivery System,
Inc., a Delaware corporation with principal offices located at 787 Seventh
Avenue, New York, New York (the "Company"), and Leonard Firestone (the
"Executive").

                                   WITNESSETH

         WHEREAS, the Executive has served as the Company's Chief Executive
Officer pursuant to a letter agreement dated November 20, 2000 (the "Employment
Letter"); and

         WHEREAS, the Company has a continuing need for the Executive's personal
services in an executive capacity; and

         WHEREAS, the Executive and the Company desire to enter into this formal
Employment Agreement, which is to take effect upon any IPO, as defined herein,
in order to fully recognize the contributions of Executive to the company and to
assure continuous harmonious performance of the affairs of the Company after
such IPO.

         NOW, THEREFORE, in consideration of the mutual promises, terms
provisions, and conditions contained herein, the parties agree as follows:

1.       Position.

         The Company hereby agrees to continue to employ the Executive to serve
in the role of Chief Executive Officer of the Company, subject to the
limitations set forth herein. As such, the Executive shall be responsible for
the business of the Company, subject to the authority of the Board of Directors
of the Company (the "Board"). The Executive accepts such employment upon the
terms and conditions set forth herein, and further agrees to perform to the best
of his abilities the duties generally associated with his position, as well as
such other duties commensurate with his position as Chief Executive Officer as
may be reasonably assigned by the Board. The Executive shall, at all times
during the Term, report directly to the Board. The Executive shall perform his
duties diligently and faithfully and shall devote his full business time and
attention to such duties, provided however, that nothing herein shall preclude
the Executive from (i) serving on the board of directors of a reasonable number
of other corporations with the prior written approval of the Board, (ii) serving
on the boards of a reasonable number of trade associations and/or charitable
organizations, (iii) engaging in charitable activities and community affairs and
(iv) managing his personal investments and affairs, provided that such
activities do not conflict or interfere with the effective discharge of his
dunes and responsibilities under this Agreement, or otherwise violate any of the
terms of this Agreement.

<PAGE>

2.       Term of Employment and Renewal.

         The term of Executive's employment under this Agreement will commence
on the date of this Agreement, which shall be the date of the Company's IPO, as
defined herein (the "Effective Date"). Subject to the provisions of Section 10
of this Agreement, the term of Executive's employment hereunder shall commence
on the Effective Date and continue until the third anniversary of the Effective
Date (the "Initial Term"). The Initial Term of this Agreement shall be
automatically extended for successive two (2) year periods (each a "Renewal
Period") unless the Company or the Executive gives written notice to the other
at least six (6) months prior to the expiration of the Initial Term, or a
Renewal Period, of such party's election not to extend this Agreement.
References herein to the "term" shall mean the Initial Term as it may be so
extended by one or more Renewal Periods. The last day of the Term is the
"Expiration Date."

3.       Compensation and Benefits.

         (a) Salary. Commencing on the Effective Date, the Company agrees to pay
the Executive a base salary at an annual rate of four hundred thousand Dollars
($400,000), payable in such installments as is the policy of the Company (the
"Salary"), but no less frequently than monthly. The Salary shall be reviewed by
the Board effective January 1, 2003, if such date falls at least (6) months
after the Effective Date. Thereafter, the Board shall, on an annual basis,
determine appropriate increases to Executive's Salary in its sole discretion but
in no event shall diminish the amount of Executive's Salary below the initial
rate, or below the increased rates unless all of the Executive's peer executives
undergo substantially equivalent reductions.

         (b) Bonus. The Executive shall be eligible to receive annual bonuses up
to a maximum of one hundred fifty percent (150%) of the Salary, according to
performance goals for both the Executive and the Company set by the Board with
input from the Executive. Performance goals shall be bet no later than
February 28 of the year in which they are to be achieved or within thirty (30)
days of the Effective Date, if the Effective Date is after February 28.

         (c) Benefits. The Executive shall be entitled to participate in any
employee incentive and benefit plans which the Company provides or may establish
from time to time for the benefit of its employees, including, without
limitation, group life, medical, surgical, dental and other health deferred
compensation, profit sharing and similar plans, in accordance with the terms of
those plans. The Company shall pay for business related professional dues, to a
maximum of $1,500 per year, medical licensing fees for one state, and
malpractice premium costs, to a maximum of $l0,000 per year. The Company shall
also reimburse the Executive for the costs, including any related tax liability,
of securing long-term disability insurance (at a rate not in excess of the
Salary) and term life insurance (in an amount not in excess of $800,000). The
Company shall pay to the Executive a monthly car and parking allowance of one
thousand Dollars ($1,000), which shall be treated as ordinary income to the
Executive. The Executive shall also be entitled to paid vacation of twenty (20)
days per year, in accordance with the Company's vacation policy which may be
accrued to a maximum of thirty (30) days. In connection with any claims against
the Executive arising out of the performance of his duties hereunder, the
Company shall defend and indemnify the Executive to the full extent permitted by
law.

<PAGE>

         (d) Stock Options. Concurrent with any underwritten public offering of
the Company's common stock pursuant to an effective registration under the
Securities Act of 1933 resulting in net proceeds to the Company of at least
twenty million Dollars ($20,000,000)(an "IPO"), the Company shall grant the
Executive, pursuant to the Company's 2001 Omnibus Stock Incentive Plan (the
"Plan"), an option to purchase 750,000 shares of the Company's common stock at a
purchase price equal to the (fair market value of the shares at the time of the
grant under the terms and conditions set forth in the Plan and the Company's
standard stock option agreement which shall be provided to the Executive upon
the date of the stock option grant provided for herein, vesting as to one-third
of the option shares upon the date of the grant and then in two (2) equal annual
installments on the first and second anniversaries of the grant date, as long as
the Executive is employed by the Company. This stock option shall be an
incentive stock option to the extent permissible under the Internal Revenue
Code.

         (e) Performance Stock Options. The Executive shall be eligible for
annual grants of stock options, up to an annual maximum of 500,000 option
shares, according to performance goals for the Company and the Executive to be
established by the Board with input from the Executive. Such stock options shall
vest as to one-third of the option shares upon the date of the grant and then in
two (2) equal annual installments on the first and second anniversaries of the
grant date, as long as the Executive is employed by the Company. Performance
goals shall be set no later than February 28 of the year in which they are to be
achieved or within thirty (30) days of the Effective Date, if the Effective Date
is after February 28.

         (f) Expense. The Company shall pay or reimburse the Executive for all
reasonable out-of-pocket expenses actually incurred by him during the Term in
performing services hereunder, provided that the Executive properly accounts for
such expenses in accordance with the Company's policies. The Executive shall be
reimbursed for business class travel, when available, taken in performance of
his job duties hereunder.

4.       Confidentiality, Disclosure of Information.

         (a) The Executive recognizes and acknowledges that the Executive has
had and will have access to Confidential information (as defined below) relating
to the business or interests of the Company or of persons with whom the Company
may have business relationships. Except as permitted herein, the Executive will
not during the Term, or at any time thereafter, use, disclose or permit to be
known by any other person or entity, any Confidential Information of the Company
(except as required by applicable law or in connection with the performance of
the Executive's duties and responsibilities hereunder). The term "Confidential
Information" means information relating to the Company's business affairs,
proprietary technology, trade secrets, patented processes, research and
development data, know-how, market studies and forecasts, competitive analyses,
pricing policies, employee lists, employment agreements (other than this
Agreement), personnel policies, the substance of agreements with customers,
suppliers and others, marketing arrangements, customer lists, commercial
arrangements or any other information relating to the Company's business that is
not generally known to the public or to actual or potential competitors of the
Company (other than through a breach of this Agreement). This obligation shall
continue until such Confidential Information becomes publicly available,

<PAGE>

other than pursuant to a breach of this Section 4 by the Executive, regardless
of whether the Executive continues to be employed by the Company.

         (b) It is further agreed and understood by and between the parties to
this Agreement that all "Company Materials," which include, but are not limited
to, computers, computer software, computer disks, tapes, printouts, source, HTML
and other code, flowcharts, schematics, design graphics, drawings, photographs,
charts, graphs, notebooks, customer lists, sound recordings, other tangible or
intangible manifestation of content, and all other documents whether printed,
typewritten, handwritten, electronic, or stored on computer disks, tapes, hard
drives, or any other tangible medium, as well as samples, prototypes, models,
products and the like, shall be the exclusive property of the Company and, upon
termination of Executive's employment with the Company, and/or upon the request
of the Company, all Company Materials, including copies thereof, as well as all
other Company property then in the Executive's possession or control, shall be
returned to and left with the Company.

5.       Inventions Discovered by Executive.

         The Executive shall promptly disclose to the Company any invention,
improvement, discovery, process formula, or method or other intellectual
property, whether or not patentable or copyrightable (collectively,
"Inventions"), conceived or first reduced to practice by the Executive, either
alone or jointly with others, while performing services hereunder (or, if based
on any Confidential Information, at any time during or after the Term), (a)
which pertain to the development of drugs for pain therapy or to any other line
of business activity of the Company, whether then conducted or then being
actively planned by the Company, with which the Executive was or is involved,
(b) which is developed using time, material or facilities of the Company,
whether or not during working hours or on the Company premises, or (c) which
directly relates to any of the Executive's work during the Term, whether or not
during normal working hours. The Executive hereby assigns to the Company all of
the Executive's, right, title and interest in and to any such Inventions. During
and after the Term, the Executive shall execute any documents necessary to
perfect the assignment of such Inventions to the Company and to enable the
Company to apply for, obtain and enforce patents, trademarks and copyrights of
any and all countries on such Inventions, including, without limitation, the
execution of any instruments and the giving of evidence and testimony, without
further compensation beyond the Executive's agreed compensation during the
course of the Executive's employment. Without limiting the foregoing, the
Executive further acknowledges that all original works of authorship by the
Executive, whether created alone or jointly with others, related to the
Executive's employment with the Company and which are protectable by copyright,
are "works made for hire" within the meaning of the United States Copyright Act,
17 U.S.C. Section 101, as amended, and the copyright of which shall be owned
solely, completely and exclusively by the Company. If any invention is
considered to be work not included in the categories of work covered by the
United States Copyright Act, 17 U.S.C. Section 101, as amended, such work is
hereby assigned or transferred completely and exclusively to the Company. The
Executive hereby irrevocably designates counsel to the Company as the
Executive's agent and attorney-in-fact to do all lawful acts necessary to apply
for and obtain patents and copyrights and to enforce the Company's rights under
this Section. This Section S shall survive the termination of this Agreement.
Any assignment of copyright hereunder includes all rights of paternity,
integrity, disclosure and

<PAGE>

withdrawal and any other rights that may be known as on referred to as "moral
rights" (collectively "Moral Rights"). To the extent such Moral Rights cannot be
assigned under applicable law and to the extent the following is allowed by the
laws in the various countries where Moral Rights exist, the Executive hereby
waives such Moral Rights and consents to any action of the Company that would
violate such Moral Rights in the absence of such consent. The Executive agrees
to confirm any such waivers and consents from time to time as requested by the
Company.

6.       Non-Competition and Non-Solicitation.

         The Executive Acknowledge that the Company has invested substantial
time, money and resources in the development and retention of its inventions,
Confidential Information (including trade secrets), customers, accounts and
business partners, and further acknowledges that during the course of the
Executive's employment with the Company the Executive has had and will have
access to the Company's Inventions and Confidential Information (including trade
secrets), and will be introduced to existing and prospective customers, accounts
and business partners of the Company. The Executive acknowledges and agrees that
any and all "goodwill" associated with any existing or prospective customer,
account or business partner belongs exclusively to the Company, including, but
not limited to, any goodwill created as a result of direct or indirect contacts
or relationships between the Executive and any existing or prospective
customers, accounts or business partners. Additionally, the parties acknowledge
and agree that Executive possesses skills that are special, unique or
extraordinary and that the value of the Company depends upon his use of such
skills on its behalf.

         In recognition of this, the Executive covenants and agrees that:

         (a) During the Term, and for a period of one (1) year thereafter, the
Executive may not, without the prior written consent of the Board, (whether as
an employee, agent, servant, owner, partner, consultant, independent contractor,
representative, stockholder or in any other capacity whatsoever) participate in
any business that offers products or services competitive in any way to those
offered by the Company or that were under active development by the Company
during the Term, provided that nothing herein shall prohibit the Executive from
owning securities of corporations which are listed on a national securities
exchange or traded in the national over-the-counter market in an amount which
shall not exceed 3% of the outstanding shares of such corporation.

         (b) During the Term, and for a period of one (1) year thereafter, the
Executive may not entice, solicit or encourage any Company employee to leave the
employ of the Company or any independent contractor to sever its engagement with
the Company, absent, prior or written consent to do so from the Board.

         (c) During the Term, and for a period of one (1) year thereafter, the
Executive may not, directly or indirectly, entice, solicit or encourage any
customer, prospective Customer, vendor, strategic partner or business associate
of the Company to cease doing business with the Company, reduce its relationship
with the Company or refrain from establishing or expanding a relationship with
the Company.

<PAGE>

7.       Non-Disparagement.

         The Executive hereby agrees that during the Term, and at all times
thereafter, the Executive will not make any statement that is disparaging about
the Company, any of its officers, directors, or shareholders, including, but not
limited to, any statement that disparages the products, services, finances,
financial condition, capabilities or other aspect of the business of the
Company. The Executive further agrees that during the same period the Executive
will not engage in any conduct that is intended to inflict harm upon the
professional or personal reputation of the Company or any of its officers,
directors, shareholders or employees. The Company likewise agrees that its
officers and directors will not make any statement that is disparaging about the
Executive and will not authorize any agent to engage in any conduct that is
intended to inflict harm on the Executive's professional or personal reputation
or to interfere with full performance of this Agreement.

8.       Provisions Necessary and Reasonable.

         (a) The Executive agrees that (i) the provisions of Sections 4, 5, 6
and 7 of this Agreement are necessary and reasonable to protect the Company's
Confidential Information, Inventions, and goodwill; (ii) the specific temporal,
geographic and substantive provisions set forth in Section 6 of this Agreement
are reasonable and necessary to protect the Company's business interests in part
because the Company's business is international in scope; and (iii) in the event
of any breach of any of the covenants set forth herein, the Company wou1d suffer
substantial irreparable harm and would not have an adequate remedy at law for
such breach. In recognition of the foregoing, the Executive agrees that in the
event of a breach or threatened breach of any of these covenants, in addition to
such other remedies as the Company may have at law, without posting any bond or
security, the Company shall be entitled to seek and obtain equitable relief, in
the form of specific performance, and/or temporary preliminary or permanent
injunctive relief, or any other equitable remedy which then may be available.
The seeking of such injunction or order shall not affect the Company's right to
seek and obtain damages or other equitable relief on account of any such actual
or threatened breach.

         (b) If any of the covenants contained in Sections 4, 5, 6 and 7 hereof,
or any part thereof, are hereafter construed so be invalid or unenforceable, the
same shall not affect the remainder of the covenant or covenants, which shall be
given full effect without regard to the invalid portions.

         (c) If any other covenants contained in Sections 4, 5, 6 and 7 hereof,
or any part thereof, are held to be unenforceable by a court of competent
jurisdiction because of the temporal or geographic scope of such provision or
the area covered thereby, the parties agree that the court making such
determination shall have the power to reduce the duration and/or geographic area
of such provision and, in its reduced form, such provision shall be
enforceable.

<PAGE>

9.       Representations Regarding Prior Work and Legal Obligations.

         (a) The Executive represents that the Executive has no agreement or
other legal obligation with any prior employer, or any other person or entity,
that restricts the Executive's ability to accept employment with, or to perform
any function for, the Company.

         (b) The Executive has been advised by the Company that at no time
should the Executive divulge to or use for the benefit of the Company any trade
secret or confidential or proprietary information of any previous employer. The
Executive expressly acknowledges that the Executive has not divulged or used
any such information, for the benefit of the Company.

         (c) The Executive acknowledges that the Executive has not and will not
misappropriate any Invention that the Executive played any part in creating
while working for any former employer.

         (d) The Executive acknowledges that the Company is basing important
business decisions on these representations, and affirms that all of the
statements included herein are true.

10.      Termination and Severance.

         Notwithstanding the provisions of Section 2 of this Agreement, the
Executive's employment hereunder may terminate under the following
circumstances:

         (a) Termination by the Company for Cause. The Company may terminate
this Agreement for Cause at any time, upon written notice to the Executive
setting forth in reasonable detail the nature of such Cause. For purposes of
this Agreement, Cause is defined as (i) the Executive's willful and material
breach of the terms of this Agreement; (ii) the Executive's commission of any
felony or any crime involving moral turpitude; or (iii) gross negligence or
willful misconduct by the Executive in connection with his position hereunder,
or (iv) the Executive's willful refusal to perform his duties hereunder. In the
case of a termination for reasons set forth in (iv) above, the Executive shall
have a fourteen (14) day period following receipt of the Company's written
notice in which to cure such Cause. Upon the termination for Cause of
Executive's employment, the Company shall have no further obligation or
liability to the Executive other than for salary earned under this Agreement
prior to the date of termination, and any accrued but unused vacation.

         (b) Termination by the Company Without Cause. The Executive's
employment hereunder may be terminated without Cause by the Company upon written
notice to the Executive, provided, however, that if the Company terminates the
Executive's employment without Cause: (i) the Company shall continue to pay the
Executive the Salary for a twelve (12) month period, or until the Expiration
Date, whichever is longer; (ii) the Company shall pay the Executive any bonuses
and any incentives earned prior to the termination date; (iii) the Company
shall pay for the costs of continuation of the Executive's health insurance
pursuant to COBRA for a twelve (12) month period; and (iv) the unvested portions
of any stock options granted to the Executive shall vest in full. As a condition
of receiving severance payments and benefits pursuant to this subsection 10(b),
the Executive shall execute and deliver to the Company prior to his/her receipt
of such benefits a general release substantially in the form attached hereto as
Exhibit A.

<PAGE>

         (c) Termination by the Executive, The Executive may terminate his
employment hereunder upon one (1) month's written notice to the Company. In the
event of termination by the Executive pursuant to this subsection 10(c), the
Company may, in lieu of permitting the Executive to continue to report to work
after giving notice, elect to pay the Executive during the notice period (or for
any remaining portion of that period) the Salary and benefits at the rate of
compensation the Executive was receiving immediately before such notice of
termination was tendered.

         (d) Death. In the event of the Executive's death during the Term of
this Agreement, the Executive's employment hereunder shall immediately and
automatically terminate, and the Company shall have no further obligation or
duty to the Executive or his estate or beneficiaries other than for the Salary
and any bonuses and any incentives earned under this Agreement to the date of
termination and any payments or benefits due under Company policies or benefit
plans.

         (e) Disability. The Company may terminate the Executive's employment
hereunder, upon written notice to the Executive, in the event that the Executive
becomes disabled during the Term through any condition of either a physical or
psychological nature and, as a result, is, with or without reasonable
accommodation, unable to perform the essential functions of the services
contemplated hereunder for (a) a period of ninety (90) consecutive days, or (b)
for shorter periods aggregating one hundred twenty (120) days during any twelve
(12) month period during the Term. Any such termination shall become effective
upon mailing or hand delivery of notice that the Company has elected its right
to terminate under this subsection 10(e), and the Company shall have no further
obligation or duty to the Executive other than for Salary and any bonuses and
any incentives earned under this Agreement prior to the date of termination and
any payments or benefit's due under Company policies or benefit plans.

         (f) Effect of Non-Renewal. In the event that the Company gives notice
of its election not to extend the Term of the Agreement for a Renewal Period
pursuant to Section 2 above, the Company shall pay to the Executive all payments
and provide to the Executive all benefits described in subsection 10(b) above
provided that in the event that the Company gives notice of its election not to
extend the Term of the Agreement (or a Renewal Period pursuant to Section 2 and
such Renewal Period expires on or after the sixth anniversary of the
Effective Date, the Company shall continue to pay the Executive full
compensation as defined in Section 3 of this Agreement from the date the
Executive receives such notice through the Expiration Date but shall not be
entitled to the payments and benefits set forth in subsection 10(b) above and
the Executive shall, not be entitled to any additional compensation other than
any payments or benefits due under Company policies or benefit plans.

         (g) Change in Control. The Executive may terminate his employment
hereunder following a Change in Control upon sixty (60) days' written notice to
the Company. Following such termination, (i) the Company shall continue to pay
the Executive the Salary for an eighteen (18) month period; (ii) the Company
shall pay the Executive any bonuses and any incentives earned prior to the
termination date; and (iii) the unvested portions of any stock options granted
to the Executive shall vest in full. As a condition of receiving severance
payments and benefits pursuant to this subsection 10(g), the Executive shall
execute and deliver to the Company prior to his receipt of such benefits a
general release substantially in the form attached hereto as

<PAGE>

Exhibit A. Notwithstanding the foregoing, the Company or its successor may
request that the Executive continue his employment under the terms and
conditions herein after a Change in Control, as described below, for a period of
no more than eighteen (18) months, if the Company or its successor makes such a
request, the Executive must continue employment for the requested period,
without a termination by the Company for Cause, death or disability or a
voluntary resignation by the Executive, as a condition of receiving, in addition
to compensation and benefits for continued employment during the requested
period, the payments and benefits set forth, in this subsection 10(g). As used
herein, a "Change of Control" shall be deemed to occur if: (i) there shall be
consummated (x) any consolidation or merger of the Company in which the Company
is not the continuing or surviving corporation or pursuant to which the stock of
the Company would be converted into cash, securities or other property, other
than a merger or consolidation of the Company in which the holders of the
Company's stock immediately prior to the merger or consolidation hold more than
fifty percent (50%) of the stock or other forms of equity of the surviving
corporation immediately after the merger, or (y) any sale, lease, exchange or
other transfer (in one transaction or a series of related transactions) of all,
or substantially all, the assets of the Company, (ii) the Board approves any
plan or proposal for liquidation or dissolution of the Company, or (iii) during
any period of twenty-four consecutive months, individuals who at the beginning
of such period constituted the Board (including for this purpose any new
director whose election or nomination for election by the Company's stockholders
was approved by a vote of at least two-thirds of the directors then still in
office who were directors at the beginning of such period) cease for any reason
to constitute at least a majority of the Board. Notwithstanding the foregoing
provisions of this subsection 10(g), a "Change in Control" will not be deemed to
have occurred as a result of an IPO.

11.      Choice of Law.

         The Executive acknowledges that a substantial portion of the Company's
business is based out of and directed from the State of New York. The Executive
also acknowledges that during the course of the Executive's employment with the
Company the Executive will have substantial contacts with New York.

         The validity, interpretation and performance of this Agreement shall be
governed by, and construed in accordance with, the internal law of New York,
without giving effect to conflict of law principles. Both parties agree that the
exclusive venue for any action, demand, claim or counterclaim relating to the
terms and provisions of Sections 4, 5, 6 and 7 of this Agreement, or to their
breach, shall be in the state or federal courts located in the State and County
of New York and that such courts shall have personal jurisdiction over the
parties to this Agreement.

12.      Miscellaneous.

         (a) Assignment. The Executive acknowledges and agrees that the rights
and obligations of the Company under this Agreement may be assigned by the
Company to any successors in interest. The Executive further acknowledges and
agrees that this Agreement is personal to the Executive and that the Executive
may not assign any rights or obligations hereunder.

<PAGE>

         (b) Withholding. All salary and bonus payments required to be made by
the Company to the Executive under this Agreement shall be subject to
withholding taxes, social security and other payroll deductions in accordance
with the Company's policies applicable to employees of the Company at the
Executive's level.

         (c) Entire Agreement. This Agreement sets forth the entire agreement
between the parties and supersedes any prior communications, agreements and
understandings, written or oral, with respect to the terms and conditions of the
Executive's employment.

         (d) Amendments. Any attempted modification of this Agreement will not
be effective, unless signed by an officer of the Company and the Executive.

         (e) Waiver of Breach. The Executive understands that a breach of any
provision of this Agreement may only be waived by an officer of the Company. The
waiver by the Company of a breach of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.

         (f) Serverability. If any provision of this Agreement should, for any
reason, be held invalid or unenforceable in any respect by a court of competent
jurisdiction, then the remainder of this Agreement, and the application of such
provision in circumstances other than those as to which it is so declared
invalid or unenforceable, shall not be affected thereby, and each such provision
of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.

         (g) Notices. Any notices, requests, demands and other communications
provided for by this Agreement shall be in writing and shall be effective when
delivered by private messenger, private overnight mail service, or facsimile as
follows (or to such other address as either party shall designate by notice in
writing to the other in accordance herewith):

                               If to the Company:

                               787 Seventh Avenue
                               New York, New York 10019
                               Attn.: Chairman

                               With a copy to:

                               Brobeck, Phleger & Harrison LLP
                               1633 Broadway, 47th Floor
                               New York, New York 10019
                               Attn:  Daniel Weisberg

                               If to Executive:

                               c/o Innovative Drug Delivery Systems, Inc.
                               787 Seventh Avenue
                               New York, New York 10019

<PAGE>

                               With a copy to:

                               Farrell & Thurman, P.C.
                               P.O. BOX 671
                               Princeton, New Jersey 08542
                               Attn: John L. Thurman

         (h) Survival. The Executive and the Company agree that certain
provisions of this Agreement shall survive the expiration or termination of this
Agreement and the termination of the Executive's employment with the Company.
Such provisions shall be limited to those within this Agreement which, by their
express and implied terms, obligate either party to perform beyond the
termination of the Executive's employment or termination of this Agreement.

         (i) Disclosure and Confidentiality. The Executive agrees to provide,
and agrees that the Company similarly may provide in its discretion, a copy of
the covenants contained in this Agreement to any business or enterprise which
the Company may directly or indirectly own, manage, operate. finance, join,
control or in which the Company participates in the ownership, management,
operation, financing or control, or with which the Company may be connected or
may become connected as an officer, director, executive, partner, principal,
agent, representative, consultant or otherwise. The Executive also agrees that
the Company may disclose a copy of this Agreement if legally required to do so,
and in connection with a partnering transaction or financing, assuming that an
appropriate confidentiality agreement is in place. The Executive further agrees
not to disclose the existence or terms of this Agreement to any person other
than the Executive's immediate family and legal, financial or accounting
professional.

         (j) Arbitration of Disputes. Any controversy or claim arising out of
this Agreement or any aspect of the Executive's relationship with the Company
including the cessation thereof (other than disputes with respect to alleged
violations of the covenants contained in Sections 4, 5, 6 or 7 hereof, and the
Company's pursuit of the remedies described in Section 8 hereof in connection
therewith) shall be resolved by arbitration in accordance with the then existing
Employment Dispute Resolution Rules of the American Arbitration Association, in
New York. New York, and judgment upon the award rendered may be entered in any
court having jurisdiction thereof. Except as awarded by the arbitrator in
accordance with applicable statutory provision, the parties shall split equally
the costs of arbitration and each party shall pay its own attorneys' fees. The
parties agree that the award of the arbitrator shall be final and binding.

         (k) Rights of Other Individuals. This Agreement confers rights solely
on the Executive and the Company. This Agreement is not a benefit plan and
confers no rights on any individual or entity other than the undersigned.

         (l) Heading. The parties acknowledge that the headings in this
Agreement are for convenience of reference only and shall not control or affect
the meaning or construction of this Agreement.

<PAGE>

         (m) Advice of Counsel. The Executive and the Company hereby acknowledge
that each party has had adequate opportunity to review this Agreement to obtain
the advice of counsel with respect to this Agreement, and to reflect upon and
consider the terms and conditions of this Agreement. The parties further
acknowledge that each party fully understands the terms of this Agreement and
has voluntarily executed this Agreement.

         IN WITNESS WHEREOF, the undersigned have duly executed this Agreement
as of the day and year set forth below.

EXECUTIVE                               INNOVATIVE DRUG DELIVERY SYSTEMS

/s/ Leonard Firestone                   By:         Mark C. Rogers, M.D.
---------------------------------          -------------------------------------
Leonard Firestone                       TITLE:            Chair
                                              ----------------------------------<PAGE>

Certain confidential portions of this Exhibit were omitted by means of blackout
of the text (the "Mark"). This Exhibit has been filed separately with the
Secretary of the Securities and Exchange Commission without the Mark pursuant to
the Company's Application for Order Granting Confidential Treatment pursuant to
Rule 406 under the Securities Act of 1933, as amended.

                                                                   Exhibit 10.11

                                                                  EXECUTION COPY

                               LICENSE AGREEMENT

         This License Agreement (hereinafter referred to as the "Agreement"),
effective as of December 14, 2001, (the "Effective Date"), is entered into among
Farmarc N.A.N.V (Netherlands Antilles), a company incorporated and registered in
the Netherlands Antilles ("Farmarc: NA.N.V.), Farmarc Netherlands B.V.
(Registration No. 2807216), a company incorporated and registered in the
Netherlands ("Farmarc"), Shimoda Biotech (Proprietary) Ltd., a corporation duly
Organized and existing under the laws of the Republic of South Africa
("Shimoda") and Innovative Drug Delivery Systems, Inc.. a corporation duly
organized and existing under the laws of the State of Delaware, U.S.A. ("IDDS"),
Farmarc, Shimoda and IDDS may each be referred to as a "party" or collectively
referred to as the "parties".

         WHEREAS, Shimoda is the owner of all of the issued and outstanding
stock of Farmarc N.A. N.V., which is the owner of all of the issued and
outstanding stock of Farmarc (Farmarc N.A. N.V. and Farmarc may be collectively
referred to as the "Farmarc Companies");

         WHEREAS, Pharmacare Limited (Registration No.1898/000252/06), the
holder of fifty percent of the issued and outstanding stock of Shimoda
("Pharmacare") is the licensee of certain rights from Janssen Pharmaceutica N.V.
("Janssen") pursuant to the Janssen Agreements as defined below including but
not limited to know-how, access to a U.S. FDA Drug Master File pertaining to
HPBCD (defined below in Paragraph 1.7) and rights to certain U.S. and foreign
patents and patent applications;

         WHEREAS, pursuant to the terms of the Janssen Agreements, Shimoda (as
an "affiliate" in the Janssen Agreements) is entitled to exercise the rights
granted to Pharmacare under such agreements;

<PAGE>

                                                                  EXECUTION COPY

         WHEREAS, IDDS desires to license from Shimoda, and Shimoda desires to
license to IDDS, the Janssen Rights (defined below) and the Shimoda Rights
(defined below);

         WHEREAS, Farmarc is the owner the Farmarc Rights (defined below);

         WHEREAS, IDDS desires to license from Farmarc, and Farmarc desires to
license to IDDS, the Farmarc Rights; and

         WHEREAS, the parties now desire to enter into this Agreement in order
to set forth their mutual understanding upon the terms and conditions
hereinafter set forth.

         NOW, THEREFORE, based on the foregoing premises, the mutual promises
set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, it is agreed as follows:

                             ARTICLE 1- DEFINITIONS

         For the purposes of this License Agreement, the following words and
phrases shall have the following meanings:

    1.1  "Affiliate" shall mean, with respect to any Entity (as hereinafter
defined), any Entity that directly or indirectly Controls, is Controlled by, or
is under common Control with such Entity.

    1.2  "Control" shall mean direct or indirect control of fifty percent
(50%) or more of the voting securities of an Entity or the possession, directly
or indirectly, of the power to direct or cause the direction of the management
and policies of such Entity, whether through the ownership of securities, by
contract or otherwise.

                                       2
<PAGE>

                                                                  EXECUTION COPY

    1.3  "Entity" shall mean any corporation, association, joint venture,
partnership, trust, university, business, individual, government or political
subdivision thereof including an agency, or any other organization that can
exercise independent legal standing.

    1.4  "Farmarc Rights" shall mean the patents and patent applications
listed in Schedule A under the heading "Farmarc Rights" and all Patent Rights
related thereto, and all Know-How owned, procured or licensed by Farmarc related
to cyclodextrin intravenous diclofenac.

    1.5  "Initial Milestones" shall mean Shimoda's fulfillment of all of the
following milestones:

         1.5.1 receipt by IDDS of the preclinical package materials set forth on
Schedule 1.5(a) hereto and assignment by Upsher-Smith Laboratories, Inc.
("Upsher-Smith") to Shimoda of all materials set forth in the agreement between
Shimoda and Upsher-Smith attached hereto as Exhibit 1;

         1.5.2 receipt by IDDS of the case report forms for the Phase I and
Phase II clinical trials as set forth on Schedule 1.5(b) hereto;

         1.5.3 execution of a letter agreement (the "Janssen Letter Agreement")
between Janssen and IDDS substantially in the form attached hereto as Exhibit 2
which provides, among other things, Janssen's consent to the sub-sublicensing of
the Janssen Rights by IDDS (x) in a Janssen Major Market, upon Janssen's
approval, which shall not be unreasonably withheld; or (y) in a non-Janssen
Major Market, without Janssen's approval. For the purposes of this Section,

                                       3
<PAGE>

                                                                  EXECUTION COPY

"Janssen Major Market" shall mean the United States, Japan, UK, France, Germany,
Italy and Spain.

         1.5.4 written evidence that the National Institute of Health ("NIH")
concurs with the sublicensing to IDDS of the Janssen Rights;

         1.5.5 submission of a binding letter of authorization by Janssen to the
FDA allowing IDDS to refer to Janssen's FDA-approved Drug Master File on file
with the FDA which pertains to hydroxypropyl-beta-cyclodextrin ("HPBCD").

    1.6  "Janssen Agreements" shall mean those license agreements which
grant to Shimoda (as Pharmacare's "Affiliate" under such agreements) the rights
to the Janssen Rights which are attached hereto as Exhibits 3A, 3B and 3C,
respectively, together with the side letters attached to the Janssen Agreements,
attached hereto and marked as Exhibits 3D and 3E.

    1.7  "Janssen Rights" shall mean all patents and patent applications and
all know-how licensed to Shimoda pursuant to the Janssen Agreements including
but not limited to the Patent Rights and Know-How described in Schedule A under
the heading "Janssen Rights", as well as any future rights licensed to Shimoda
under the terms of Addendum 2 to the Worldwide License Agreement, as attached
hereto as Exhibit 3B.

    1.8  "Know-How" shall mean all information (other than that contained in
the Patent Rights) whether patentable or not (but which have not been patented)
related to the Patent Rights or to the Licensed Product or Licensed Processes,
including the know-how set out in Schedule A and including but not limited to
processes, techniques, data, methods, compositions, trade secrets, formulations,
materials, data, drawings and sketches, designs, testing and test results

                                       4
<PAGE>

                                                                  EXECUTION COPY

(including but not limited to toxicological, pharmacological, clinical and
chemical data) and regulatory information of a like nature.

    1.9  "Licensed Process(es)" shall mean any process or method, which is
covered, in whole, or in part, by a valid and unexpired claim contained in the
Patent Rights in the country in which the process or method is used.

    1.10 "Licensed Product(s)" shall mean:

         1.10.1 Any product which is covered in whole or in part by a valid and
unexpired claim contained in the Patent Rights in the country in which the
product is made, used, leased or sold; and

         1.10.2 Any product which is used according to a method or process which
is covered in whole or in part by a valid and unexpired claim contained in the
Patent Rights in the country in which the method or process is used.

    1.11 "Licensed Rights" shall mean the Patent Rights and the Know-How,
collectively.

    1.12 "Major Market" shall mean any of the United States, the member states
of the European Union, the UK or Japan.

    1.13 "Net Sales" shall mean the amount billed, invoiced or received
(whichever is first) on sales of Licensed Products or practice of Licensed
Processes by or on behalf of IDDS or any of its Affiliates or sublicensees, less
only the sum of the following:

                                       5
<PAGE>

                                                                  EXECUTION COPY

         1.13.1 Customary trade, quantity, or cash discounts and non-affiliated
brokers' or agents' commissions actually allowed and taken and rebates,
including but not limited to government mandated rebates;

         1.13.2 Amounts repaid or credited by reason of rejections or return;
and/or

         1.13.3 Any freight or other transportation costs, insurance charges,
duties, tariffs and all sales and excise taxes based directly on sales or
turnover or delivery of Licensed Products or practice of the Licensed Processes
produced under this Agreement.

    1.14 "Patent Rights" shall mean:

         1.14.1 All U.S. and foreign patents and patent applications set forth
in Schedule A and other patent applications now in progress but not yet filed;
and

         1.14.2 Any other United States and/or foreign patent applications
and/or patents, together with any and all patents issuing thereon, including
parent patents, continuation, divisionals and re-issue applications,
re-examinations and continuation-in-part applications and any United States or
foreign patents granted upon such applications, based upon inventions or
improvements, modifications, variations or other applications of or to the
Licensed Rights discovered by or under the direct or indirect direction of
Shimoda, any and all of which shall be deemed added to Schedule A; and

         1.14.3 Any later-filed United States and/or foreign patent applications
based on the patent applications and/or patents listed in Schedule A, or
corresponding thereto, including any continuations, continuations-in-part,
divisional, reissues, reexaminations, or extensions thereof; and

                                       6
<PAGE>

                                                                  EXECUTION COPY

         1.14.4 Any United States and/or foreign patents issuing from any of the
foregoing.

    1.15 "Shimoda Group" shall mean Shimoda and all of its subsidiaries
(including but not limited to the Farmarc Companies), collectively. For purposes
of this Agreement, "subsidiary" shall mean any corporation, partnership, limited
partnership, limited liability company, joint venture or other legal entity of
which a Person owns directly, or indirectly, a majority of the stock or other
equity interests.

    1.16 "Shimoda Rights" shall mean all rights which Shimoda has or may
have in and to the Patent Rights listed in Schedule A together with all related
Know-How owned, procured or licensed by Shimoda, including the Shimoda Know-How
listed in Schedule A.

                     ARTICLE 2-LICENSE GRANTS; SUBLICENSES

    2.1  Shimoda Grants to IDDS.

         2.1.1 Shimoda hereby grants to IDDS during the term of this Agreement,
and IDDS hereby accepts, an exclusive (subject only to the provisions of
Paragraph 2.1.2, below) worldwide license in all fields of use to practice under
the Shimoda Rights, and to make, have made, use, import, lease and/or sell the
Licensed Products and to practice the Licensed Processes. The foregoing license
grants shall be fully sublicensable and transferable by IDDS.

         2.1.2 Shimoda hereby retains an irrevocable, royalty-free right to use
the technology, ideas and enhancements reflected in the Shimoda Rights solely
for its own internal non-commercial research use.

                                       7
<PAGE>

                                                                  EXECUTION COPY

         2.1.3 Shimoda hereby grants to IDDS during the term of this Agreement
and IDDS hereby accepts, an exclusive worldwide license in the field of
intramuscular and Intravenous injectable formulations of pharmaceutical products
containing HPBCD and diclofenac as an active ingredient to practice under the
Janssen Rights and to make, have made, use, import, lease and/or sell the
Licensed Products and to practice the Licensed Processes. IDDS shall have the
right to sublicense its rights hereunder to the Janssen Rights (x) in a Janssen
Major Market, upon Janssen's approval, which shall not be unreasonably withheld;
or (y) in a non-Janssen Major Market, without Janssen's approval. For the
purposes of this Section, "Janssen Major Market" shall mean the United States,
Japan, UK, France, Germany, Italy and Spain.

         2.1.4 IDDS shall enter into an appropriate written agreement with each
such permitted sublicensee. Within thirty (30) days after execution, IDDS shall
provide Shimoda with a copy of each sublicense issued hereunder to determine
IDDS's compliance with the terms of this Agreement.

    2.2  Farmarc Grant to IDDS. Farmarc hereby grants to IDDS during the
term of this Agreement and IDDS hereby accepts, an exclusive, worldwide license
in all fields of use to practice under the Farmarc Rights and to make, have
made, use, import, lease and/or sell the Licensed Products and to practice the
Licensed Processes. The foregoing license grants shall be fully sublicensable
and transferable by IDDS.

    2.3  Upon termination of this Agreement other than by expiration, any
and all sublicenses shall survive such termination. In the event such
sublicenses survive, IDDS shall

                                       8
<PAGE>

                                                                  EXECUTION COPY

continue to pay royalties owed to Shimoda or Farmarc pursuant to the terms of
this Agreement (other than in the event the Agreement is terminated due to a
breach by Shimoda Farmarc).

                      ARTICLE 3 - COVENANTS OF THE PARTIES

    3.1  By IDDS.

         3.1.1 IDDS shall use its commercially reasonable efforts to bring
Licensed Products or Licensed Processes to market through a thorough, vigorous
and diligent program for exploitation of the Patent Rights and Know-How and
shall continue active, diligent marketing efforts for Licensed Products or
Licensed Processes throughout the life of this Agreement. IDDS shall comply with
the commercialization timelines set forth in the Janssen Letter Agreement.

         3.1.2 In the event IDDS plans to pursue the acquisition of technology
incorporating the use of cyclodextrins, IDDS shall first approach Shimoda with
respect to such acquisition.

         3.1.3 Insurance.

               3.1.3.1 Immediately upon the execution of this agreement and
for a period of three years after the completion of the relevant clinical trial,
IDDS shall obtain and/or maintain, at its sole cost and expense, clinical trial
insurance in the United States in amounts which are reasonable and customary in
the United States pharmaceutical industry, subject always to a minimum limit of
US$*** dollars per occurrence (or claim) and in aggregate annually in
respect of all or any clinical trials which IDDS, its affiliates, agents or
employees may undertake in respect of one or more of the Licensed Products. Such
clinical trial insurance shall insure against all liability, including product
liability, personal liability or physical injury.

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       9

<PAGE>

                                                                  EXECUTION COPY

               3.1.3.2 By no later than the date on which one or more of the
Licensed Product(s) are first offered for sale in any territory and for a period
of five years after the expiration of the Agreement or early termination
thereof, IDDS shall obtain or maintain, at its sole cost and expense, worldwide
product liability insurance in amounts which are then reasonable and customary
in the United States pharmaceutical industry. In respect of the foregoing, IDDS
and Shimoda shall select a mutually acceptable third party knowledgeable in the
United States pharmaceutical insurance industry who shall determine what
amount(s) are reasonable and customary in the United States pharmaceutical
industry.

               3.1.3.3 Shimoda may request of IDDS written proof of the
existence of any such insurance. In the event IDDS does not provide Shimoda with
written proof of the existence of the necessary insurance within 14 (fourteen)
days of the appropriate request therefor, Shimoda shall be entitled to terminate
this Agreement upon 15 (fifteen) days' written notice, provided, however, that
during such 15 (fifteen) day period IDDS's breach has not been cured.

    3.2  By Shimoda.

         3.2.1 Shimoda shall use its best efforts to cause Pharmacare to (i)
comply with its obligations under the Janssen Agreements and (ii) reasonably
cooperate with Shimoda and IDDS to facilitate the relationship among Janssen,
Shimoda and IDDS.

         3.2.2 Shimoda agrees that IDDS shall not have any obligation to Janssen
under the Janssen Agreements or any other agreement between Shimoda (or
Pharmacare) and Janssen, at any time, unless otherwise expressly agreed to in
writing by IDDS and Janssen. Shimoda

                                       10
<PAGE>

                                                                  EXECUTION COPY

represents that the agreements attached as Exhibits 3A through 3E have not been
redacted and constitute the complete agreement between Janssen and
Pharmacare/Shimoda.

         3.2.3 Shimoda shall use its best efforts to fulfill the Initial
Milestones as soon as reasonably practicable, but in all events no later than
ninety (90) days after the Effective Date. Shimoda shall promptly notify IDDS in
writing when each initial Milestone is met, and IDDS shall have fifteen (15)
days in which to acknowledge in writing the fulfillment of each such Initial
Milestone.

         3.2.4 Shimoda agrees that during the term of this Agreement, it shall
not acquire, develop or further or assist a third party in acquiring, developing
or furthering any technology or product related to nasally delivered ketamine,
morphine, midazolam (other than midazolam with cyclodextrins), diclofenac or
fentanyl.

         3.2.5 During the three year period commencing on the Effective Date
(which three year period may be successively renewed by Shimoda and IDDS's
written agreement prior to the expiration of any three year term), Shimoda shall
not grant to any third party any right or license under any of Shimoda's
intellectual property rights or proprietary rights involving the use of any
cyclodextrin product related to pain management, anesthesia or sedation (the
"New Technology") without first offering to IDDS the right to procure the same
right or license upon the same terms. Shimoda shall promptly notify IDDS in
writing of its intention to license or dispose of the New Technology along with
a summary of the proposed terms (the "New Technology Offer") and IDDS shall have
30 days, after receipt of said New Technology Offer, to notify Shimoda in
writing of its desire to negotiate a transaction with respect to such New
Technology (the "Acceptance Notice"). If IDDS provides an Acceptance Notice to
Shimoda,

                                       11
<PAGE>

                                                                  EXECUTION COPY

Shimoda and IDDS shall use their good faith and best efforts to negotiate and
execute a mutually acceptable letter of intent evidencing their agreements
covering such New Technology within 60 days of the Acceptance Notice. If IDDS
does not provide an Acceptance Notice to Shimoda, Shimoda shall be free to
license or dispose of the New Technology to a third party upon the same terms
offered to IDDS. In the event that Shimoda intends to offer the New Technology
to a third party upon different or more favorable terms than those offered to
IDDS, Shimoda shall first offer such different terms to IDDS by providing
another New Technology Offer and Shimoda and IDDS shall again begin the above
procedures.

    3.3  By The Farmarc Companies and Shimoda.

         3.3.1 Each of the Farmarc Companies and Shimoda hereby covenants that
during the term of this Agreement there shall be no conveyance, mortgage,
pledge, lease, sale, assigment, transfer, license or other encumbrance of the
Farmarc Rights involving any party other than Shimoda or IDDS.

                  ARTICLE 4- ROYALTIES AND OTHER CONSIDERATION

         In consideration for the licenses granted herein, IDDS shall make the
following payments:

    4.1  A license fee to Shimoda in the amount of $*** which shall be
payable in two equal installments as set forth in Sections 4.1.1 and 4.1.2,
below, as follows:

         4.1.1 A non-refundable cash payment in the amount of $*** to be
paid as follows: (i) upon execution of this License Agreement, $*** to
Upsher-Smith on behalf of

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       12

<PAGE>

                                                                  EXECUTION COPY

Shimoda and $*** to Janssen on behalf of Shimoda; and (ii) upon the Initial
Milestones having been met, the balance of $*** to Shimoda; and

         4.1.2 Provided the Initial Milestones have been met, a cash payment to
Shimoda in the amount of $*** to be paid on the earlier of: (i) within
thirty (30) days of the full allowance of the first filed Investigational New
Drug Application ("IND") with the United States Food and Drug Administration
("FDA") relating to the Licensed Rights; or (ii) February 28, 2002.

    4.2  Provided that the Initial Milestones have been met, other fees and
expenses in cash as follows:

         4.2.1 A payment to Upsher-Smith on behalf of Shimoda in the amount of
$*** which represents *** per cent (***%) of the documented expenses
reasonably and actually incurred by Shimoda in connection with Shimoda's
purchase of the preclinical toxicology package from Upsher-Smith, which shall be
payable as follows: (i) $*** upon IDDS's receipt and approval (which shall
not be unreasonably withheld) of the preclinical toxicology package from
Upsher-Smith; and (ii) $*** within thirty (30) days of the full allowance of
the first filed IND with the FDA relating to the Licensed Rights.

         4.2.2 To Shimoda and Farmarc (to be divided as set forth in the last
sentence of this Section 4.2.2): a sum equal to two per cent (2%) of the
proceeds of IDDS's initial public offering ("IPO")(which proceeds shall be net
of customary offering expenses and underwriter discounts and commissions) (the
"Two Percent"). The Two Percent shall be payable within thirty (30) days, of
IDDS's receipt thereof; provided, however, that if the Two Percent (a) is less
than $1,000,000, the sum payable pursuant to this Paragraph 4.2.2 shall be
$1,000,000 or (b) is

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       13

<PAGE>

                                                                  EXECUTION COPY

greater than $2,000,000, the sum payable pursuant to this Paragraph 4.2.2 shall
be $2,000,000. The Two Percent shall be payable by IDDS as follows: 75% to
Shimoda and 25% to Farmarc.

    4.3  Provided that the Initial Milestones have been met, IDDS shall pay
to Shimoda certain milestone payments, as follows:

         4.3.1 A cash payment in the amount of $*** within 90 days of submission
of the first New Drug Application ("NDA") for a Licensed Product with the FDA,
provided that IDDS has not then received a "Refuse-To-File Letter" from the FDA;

         4.3.2 A cash payment in the amount of $*** within thirty (30) days of
IDDS's receipt of the first "Approvable Letter" from the FDA relating to an NDA
for a Licensed Product; and

         4.3.3 A cash payment in the amount of $*** payable on the date that is
one (1) year from the date of the first commercial sale by IDDS of a Licensed
Product in a Major Market.

         4.3.4 Shimoda shall have the right, but not the obligation, to elect to
receive the payments described in paragraphs 4.3.1 through 4.3.3 in equity as
promptly as practicable after the applicable milestone payment accrues, subject
to the negotiation and execution of definitive documentation in form and
substance reasonably satisfactory to each of Shimoda and IDDS and in compliance
with applicable securities laws. Shimoda shall make such election by providing
written notice thereof to IDDS. In the event that Shimoda elects to receive any
such payment in equity, Shimoda shall be entitled to receive a number of shares
of Common Stock of IDDS equal to the quotient determined by dividing $*** by one
of the following: (i) if the

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       14

<PAGE>

                                                                  EXECUTION COPY

consummation of IDDS's IPO occurs on or prior to the date on which the
applicable milestone payment has accrued, the offering price per share of Common
Stock sold in IDDS's IPO or (ii) if the consummation of IDDS's IPO occurs after
the date on which the applicable milestone payment has accrued, the price per
share of Common Stock as determined in good faith by the board of directors of
IDDS (the "Board") following consultation with an independent third-party
appraiser or investment bank selected by the Board and approved by Shimoda.

         4.4 Subject to all of the terms and conditions of this Agreement, IDDS
shall pay to Shimoda and Farmarc royalties as set forth below. *** percent
(***%) of all royalties due shall be paid to Shimoda, and *** percent (***%) of
all royalties due shall be paid to Farmarc.

         4.4.1 On a country by country basis, a royalty equal to *** percent
(***%) of Net Sales in said country.

         4.4.2 On a country by country basis and for a period of fifteen (15)
years from the Effective Date, a royalty of *** percent (***%) of the sales
revenue with regard to products and processes covered by the Know-How. For the
purposes of this agreement, "sales revenue" shall mean the amount billed,
invoiced or received (whichever is first) on products and processes covered by
the Know-How by or on behalf of IDDS or any of its Affiliates or sublicensees,
less only the sum of the following: (a) customary trade, quantity, or cash
discounts and non-affiliated brokers' or agents' commissions actually allowed
and taken and rebates, including but not limited to government mandated rebates;
(b) amounts repaid or credited by reason of rejections or return; and/or (c) any
freight or other transportation costs, insurance charges, duties, tariffs

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       15

<PAGE>

                                                                  EXECUTION COPY

and all sales and excise taxes based directly on sales or turnover or delivery
such products or processes

    4.5  The royalties payable to Shimoda and Farmarc hereunder are
inclusive of all royalties which may be due and payable to any third party with
respect to the technology licensed hereunder, and the payment of any and all
such royalties which may be owed to third parties shall be the sole
responsibility of Shimoda and Farmarc.

    4.6  There shall be no multiple or double counting of any royalties.
Each sale of any one Licensed Product or sale based on the performance of a
Licensed Process shall be subject to at most one royalty payment chosen from the
foregoing paragraphs, regardless of whether such Licensed Product or Licensed
Process is, or shall be, covered by more than one valid and unexpired claim
contained in the Patent Rights or is also considered Know-How. Therefore, the
maximum royalty possible on any given sale is *** (***%) whether sold by IDDS or
an Affiliate or subllcensee.

    4.7  In the event that a Licensed Product is sold in the form of a
combination product containing one or more products or technologies which are
themselves not a Licensed Product or Licensed Process, the Net Sales for such
combination product shall be calculated by multiplying the sales price of such
combination product by the fraction A/(A+B) where A is the invoice price of the
Licensed Product (except that in the case of a sale to an Affiliate, A shall be
the Fair Market Value of the Licensed Product) and B is the total invoice price
of the other products or technologies (except that in the case of a sale to an
Affiliate, B shall be the Fair Market Value of the other products or
technologies). In the case of a combination product which includes one or more
Licensed Products, the Net Sales for such combination product upon which the
royalty due

***Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the Commission.

                                       16

<PAGE>

                                                                  EXECUTION COPY

to Shimoda is based shall not be less than the normal aggregate Net Sales for
such Licensed Product.

    4.8  Royalty payments and any payments made pursuant to Paragraph 4.4 of
this Agreement shall be paid in United States dollars in New York, New York or
at such other place as Shimoda or Farmarc may reasonably designate consistent
with the laws and regulations controlling in any foreign country. Any
withholding taxes which IDDS, its Affiliates or any sublicensee shall be
required by law to withhold on remittance of the royalty payments shall be
deducted from such royalty payment to Shimoda and Farmarc. IDDS shall furnish
Shimoda and Farmarc with the original copies of all official receipts for such
taxes. If any currency conversion shall be required in connection with the
payment of royalties hereunder, such conversion shall be made by using the
exchange rate prevailing at Citibank, N.A. (or such applicable successor entity)
in New York, New York on the last business day of the calendar quarter to which
such royalty payments relate.

    4.9  Royalties payable to Shimoda and Farmarc hereunder shall be paid
quarter-annually in arrears, commencing at the end of the calendar quarter
during which IDDS first receives income from the sale of Licensed Product.

    4.10 To the extent that IDDS, a sublicensee or any Affiliate of IDDS is
required to obtain in any jurisdiction any license from a third party
(specifically including but not limited to Janssen) in order to practice the
rights purported to be granted to IDDS by Shimoda and Farmarc hereunder, then
IDDS may deduct all costs and expenses related to procuring and maintaining such
license and participating in all related court proceedings, including attorneys'
fees, from royalty payments due hereunder, provided that in no event shall the
aggregate royalties payable

                                       17
<PAGE>

                                                                  EXECUTION COPY

to Shimoda or Farmarc in any quarterly period be reduced by more than fifty per
cent (50%) as a result of any such deduction, provided further that any excess
deduction remaining as a result of such limitation may be carried forward to
subsequent periods. In the event IDDS is required to procure a license from
Janssen, the foregoing 50% cap on the reduction in royalties shall not apply.

                         ARTICLE 5- REPORTS AND RECORDS

    5.1  IDDS shall keep full, true and accurate books of account containing
all particulars that may be necessary for the purpose of showing the amounts
payable to Shimoda and Farmarc by way of royalty as aforesaid. Said books of
account shall be kept at IDDS's principal place of business and the supporting
data shall be open for inspection up to twice per year, upon reasonable notice
to IDDS, for two (2) years following the end of the calendar year to which they
pertain by Shimoda (on behalf of itself and Farmarc) through Shimoda's internal
audit division or by another designated auditor selected by Shimoda, except one
to whom IDDS has reasonable objection, for the purpose of verifying IDDS's
royalty payments hereunder. If an inspection shows an under reporting or
underpayment in excess of the greater of fifty thousand dollars ($50,000) or two
percent (2%) of royalties payable for any twelve (12) month period, then IDDS
shall pay to Shimoda and/or Farmarc, as appropriate, the royalties due and shall
reimburse Shimoda or Farmarc for the cost of the inspection at the time IDDS
pays the unreported royalties, including any late charges as required by
paragraph 5.4 of this Agreement. All payments required under this Article 5
shall be due within sixty (60) days of the date Shimoda provides IDDS notice of
the payment due.

    5.2  Within sixty (60) days from the end of each calendar quarter. IDDS
shall deliver to Farmarc and Shimoda complete and accurate reports, giving such
particulars of the business

                                       18
<PAGE>

                                                                  EXECUTION COPY

conducted by IDDS, its sublicensees and Affiliates during the preceding quarter
under this License Agreement as shall be pertinent to a royalty accounting
hereunder. These reports shall include at least the following:

         5.2.1 All Licensed Products and Licensed Processes used, leased or
sold, by or for IDDS, its sublicensees and Affiliates (including the number of
units sold).

         5.2.2 Total amounts invoiced for Licensed Products and Licensed
Processes used, leased or sold, by or for IDDS, its sublicensees or its
Affiliates.

         5.2.3 Deductions applicable in computing Net Sales.

         5.2.4 Total royalties due based on Net Sales by or for IDDS, its
sublicensees and Affiliates.

         5.2.5 Names and addresses of all sublicensees and Affiliates of IDDS.

         5.2.6 On an annual basis, IDDS's year-end audited financial statements.

    5.3  With each such quarterly report submitted, IDDS shall pay to
Shimoda and Farmarc the royalties due and payable under this Agreement. If no
royalties shall be due, IDDS shall not be required to make a report pursuant to
this Article 5.

    5.4  Amounts which are not paid when due and which are not the subject
of a bona fide dispute shall accrue interest from the due date until paid, at a
rate equal to the then prevailing prime rate of Citibank, N.A. (or such
applicable successor entity), plus two percent (2%).

                                       19
<PAGE>

                                                                  EXECUTION COPY

    5.5  IDDS agrees to forward to Shimoda annually a copy of any report
that is in substance similar to the report required by this Article 5, received
from any sublicensee and other documents received from any sublicensee as
Shimoda may reasonably request, as may be pertinent to an accounting of
royalties.

    5.6  Shimoda may provide such reports delivered by IDDS pursuant to
this Article 5 to its licensors and affiliates as required by its contractual
obligations, but otherwise agrees to hold (and shall cause its licensors and
affiliates to hold) in confidence each report delivered by IDDS pursuant to this
Article 5 as Confidential Information pursuant to Article 17 herein.

                 ARTICLE 6 - PATENT PROSECUTION AND MAINTENANCE

    6.1  IDDS shall diligently prosecute and maintain the Patent Rights,
including, but not limited to, the filing of patent applications which may be
required, utilizing such patent counsel chosen by IDDS but who shall be
reasonably acceptable to Shimoda and Farmarc. IDDS agrees to keep Shimoda and
Farmarc reasonably well informed with respect to the status and progress of any
such applications, prosecutions and maintenance activities and shall consult in
good faith with Shimoda and Farmarc with respect thereto. Each of Shimoda,
Farmarc and IDDS agree to provide reasonable cooperation to each other to
facilitate the application and prosecution of patents pursuant to this
Agreement. Other than in connection with Paragraph 6.2 herein, IDDS shall
reimburse Shimoda and/or Farmarc or pay patent counsel directly for all future
reasonable out-of-pocket expenses incurred for the preparation, filing,
prosecution and maintenance of Patent Rights within sixty (60) days from receipt
by IDDS of appropriate documentation of such expenses by Shimoda or Farmarc.

                                       20
<PAGE>

                                                                  EXECUTION COPY

     6.2 IDDS may, in its discretion, elect to abandon any patent applications
or issued patent comprising the Patent; Rights. Prior to any such abandonment,
IDDS shall give Shimoda or Farmarc, as licensor as the case may be, at least
sixty (60) days notice and a reasonable opportunity to take over prosecution of
such Patent Rights. In such event, Shimoda or Farmarc shall have the right, but
not the obligation, to commence or continue such prosecution and to maintain any
such Patent Rights under its own control and at its own expense. IDDS agrees to
cooperate in such activities, including execution of any assignments or other
documents necessary to enable Shimoda and Farmarc to obtain and retain sole
ownership and control of such Patent Rights.

                             ARTICLE 7- TERMINATION

     7.1 Should IDDS fail to make payment to Shimoda or Farmarc of the payments
as set out in Sections 4.1, 4.2 or 4.3 or should IDDS fail to pay the royalties
due in accordance with the terms of this Agreement that are not the subject of a
bona fide dispute between Shimoda and IDDS, then Shimoda or Farmarc as the case
may be shall have the right to terminate the rights granted by it to IDDS under
this License Agreement upon sixty (60) days' written notice unless IDDS shall
pay to Shimoda, within the 60-day period, all such amounts due and payable.

     7.2 Upon any material breach or defat4t of this License Agreement by
Shimoda or IDDS, then Shimoda or IDDS (and not the Farmarc Companies, who shall
have no such rights) shall have the right to terminate this Agreement and the
rights, privileges and licenses granted hereunder in the event such breach is
not cured within sixty (60) days of written notice to the breaching party of
such breach.

                                       21
<PAGE>

                                                                  EXECUTION COPY

     7.3 Upon any material breach or default of this License Agreement by
Farmarc, IDDS shall have the right to terminate this Agreement and the rights,
privileges and license granted hereunder in the event such breach is not cured
within sixty (60) days of written notice to the breaching party of such breach.

     7.4 Should (i) any of the Initial Milestones fail to be completed within
ninety (90) days of the Effective Date, or (ii) the FDA reject the IND referred
to in Section 4.1.2, Shimoda and Farmarc shall immediately refund all amounts
which have been paid to Shimoda and Farmarc hereunder other than the Initial
Payment and IDDS shall have the right to terminate this Agreement immediately
upon written notice to the parties hereto.

     7.5 IDDS shall have the right at any time to terminate this Agreement in
whole or as to any portion of the Licensed Rights by giving ninety (90) days
notice thereof in writing to the other parties hereunder. In the event IDDS
terminates this Agreement in its entirety pursuant to this Section 7.5, or if
the Agreement is terminated by Shimoda for IDDS's breach, then IDDS shall assign
to Shimoda (at no cost to Shimoda) all clinical information and other data
developed by IDDS in furtherance of the development of Licensed Products.

     7.6 Upon termination of this Agreement for any reason, nothing herein shall
be construed to release any party from any obligation that accrued prior to the
effective date of such termination. Paragraphs 2.3 and 7.6 and Articles 8, 10,
11, 14 and 16 through 18 shall survive the termination or expiration of this
Agreement.

     7.7 IDDS and/or any sublicensee thereof may, during the six month period
immediately following termination of this Agreement, complete the manufacture of
all Licensed Products in the process of manufacture at the time of such
termination, and sell the same,

                                       22
<PAGE>

                                                                  EXECUTION COPY

provided that IDDS shall pay or cause to be paid to Shimoda and Farmarc the
royalties thereon as required by Article 4 of this License Agreement and shall
submit the reports required by Article 5 hereof on the sales of Licensed
Products.

                    ARTICLE 8 - ARBITRATION AND GOVERNING LAW

     8.1 Except as set forth below, all disputes arising from or relating to
this Agreement that are not first settled by good faith negotiations among
Shirnoda, the Farmarc Companies and IDDS within 90 days from the date notice of
the dispute is sent from one party to the other shall be settled before a single
arbitrator (who shall be selected jointly by the disputing parties or, if such
parties fail to so agree, by the American Arbitration Association) in New York,
New York in accordance with the rules of the American Arbitration Association.

     8.2 Any claim, dispute, or controversy concerning the validity,
enforceability, or infringement of any patent contained in the Patent Rights
licensed hereunder, and all issues relating to the ownership of intellectual
property rights, shall be resolved in any court having jurisdiction thereof
located within the County and State of New York. Shimoda, the Farmarc Companies
and IDDS hereby irrevocably consent to the venue and personal jurisdiction of
such courts.

     8.3 In the event that, in any arbitration proceeding, any issue shall arise
concerning the validity, enforceability, or infringement of any patent contained
in the Patent Rights licensed hereunder, or relating to the ownership of
intellectual property rights, the arbitrators shall, to the extent possible,
resolve all issues other than validity, enforceability, infringement and
intellectual property ownership. In any event, the arbitrator shall not delay
the arbitration proceeding for the purpose of obtaining or permitting any party
to obtain judicial resolution of such issues, unless

                                       23
<PAGE>

                                                                  EXECUTION COPY

an order staying the arbitration proceeding shall be entered by a court of
competent jurisdiction. No party shall raise any issue concerning intellectual
property rights or the validity, enforceability, or infringement of any patent
contained in the Patent Rights licensed hereunder, in any proceeding to enforce
any arbitration award hereunder, or in any proceeding otherwise arising out of
any such arbitration award.

     8.4 The costs of such arbitration shall be borne by each of the parties in
an amount proportionate to the finding of fault as determined by the arbitrator.
Judgment on the arbitration award may be entered by any court of competent
jurisdiction.

                    ARTICLE 9 - INFRINGEMENT AND OTHER ACTIONS

     9.1 Each of IDDS, Shimoda and Farmarc shall promptly provide written notice
to IDDS, Shimoda and Farmarc of any alleged infringement by a third party of the
Patent Rights and provide such other parties with any available evidence of such
infringement.

     9.2 During the term of this Agreement, IDDS shall have the right, but not
the obligation, to prosecute and/or defend, at its own expense and utilizing
counsel of its choice, any infringement of, and/or challenge to, the Patent
Rights. In furtherance of such right, Shimoda and Farmarc hereby agree that
IDDS may join Shimoda and/or Farmarc as a party in any such suit, without
expense to Shimoda or Farmarc. No settlement, consent judgment or other
voluntary final disposition of any such suit which would adversely affect the
rights of Shimoda or Farmarc may be entered into without the consent of Shimoda
or Farmarc (as the case may be), which consent shall no; be unreasonably
withheld.

     9.3 If, within 90 days after receiving notice of any alleged infringement,
IDDS shall have been unsuccessful in persuading the alleged infringer to desist,
or shall not have brought

                                       24
<PAGE>

                                                                  EXECUTION COPY

and shall not be diligently prosecuting an infringement action, or if IDDS shall
notify Shimoda (if the alleged infringement relates to the Shimoda Rights) or
Farmarc (if the alleged infringement relates to the Farmarc Rights), at any
time prior thereto, of its intention not to bring suit against the alleged
infringer, then, and in those events only, Shimoda or Farmarc (as the case may
be) shall have the right, but not the obligation, to prosecute, at its own
expense and utilizing counsel of its choice, any infringement of the Patent
Right, and Shimoda or Farmarc may, for such purposes, join IDDS as a party
plaintiff. The total cost of any such infringement action commenced solely by
Shimoda or Farmarc shall be borne by Shimoda or Farmarc and such party shall
keep any recovery or damages for infringement or otherwise derived therefrom and
such shall not be applicable to any royalty obligation of IDDS.

     9.4 Any recovery of damages by IDDS, in any such suit, shall be applied
first in satisfaction of any unreimbursed expenses and legal fees of IDDS
relating to the suit and then to Shimoda and Farmarc for any royalties credited
in accordance with paragraph 9.6 below. The balance remaining from any such
recovery shall be treated as Net Sales received by IDDS in accordance with
paragraph 4.1 hereof.

     9.5 In the event that a claim or suit is asserted or brought against IDDS
alleging that the manufacture or sale of any Licensed Product by IDDS, an
Affiliate of IDDS, or any sublicensee, or the use of such Licensed Product,
infringes the proprietary rights of a third party, IDDS shall give written
notice thereof to Shimoda and Farmarc. IDDS may, in its sole discretion, modify
such Licensed Product to avoid such infringement and/or may settle on terms that
it deems advisable in its sole discretion, subject to paragraph 9.2. Otherwise,
IDDS shall have the right, but not the obligation, to defend any such claim or
suit. In the event IDDS elects

                                       25
<PAGE>

                                                                  EXECUTION COPY

not to defend such suit, each of Shimoda and Farmarc shall have the right, but
not the obligation, to do so at its sole expense.

     9.6 IDDS may credit any litigation costs incurred by IDDS in any country
pursuant to this Article 10 and any amounts paid in judgment or settlement of
litigation within this Article 10 against royalties thereafter payable to
Shimoda or Farmarc hereunder for such country. If such aggregate amounts in such
country exceed 50% of royalties payable to Shimoda or Farmarc in any year in
which such costs are incurred, then the amount of such costs, expenses and
amounts paid in judgment or settlement in excess of such 50% of the royalties
payable shall be carried over and credited against royalty payments in future
years for such country.

     9.7 In any suit to enforce and/or defend the Patent Rights pursuant to this
License Agreement, the party not in control of such suit shall, at the request
and expense of the controlling party, cooperate in all respects and, to the
extent possible, have its employees testify when requested and make available
relevant records, papers, information, samples, specimens, and the like.

      ARTICLE 10 - REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY

     10.1 By Shimoda.

          lO.1.1 Shimoda represents and warrants to IDDS that (i) subject only
to the rights of Janssen set forth in the Janssen Agreements, Shimoda has the
full power and authority to enter into this Agreement and to grant to IDDS the
rights granted herein; (ii) other than the rights which are sublicensed
hereunder (to which Shimoda has all rights to license), it has all right, title,
and interest in and to the Licensed Rights, including exclusive, absolute,
irrevocable right,

                                       26
<PAGE>

                                                                  EXECUTION COPY

title and interest thereto, free and clear of all liens, charges, encumbrances
or other restrictions or limitations of any kind whatsoever; (iii) there are no
third parry government of other consents (other than the Consents) which are or
may be required for IDDS to exercise the rights granted to it herein, or other
licenses, options, restrictions, liens, rights of third parties, disputes,
royalty obligations, proceedings or claims (a) relating to, affecting, or
limiting its rights or the rights granted to IDDS under this Agreement, or (b)
which may lead to a claim of infringement or invalidity regarding, any part or
all of the Licensed Rights and their use as contemplated in the underlying
patent applications as presently drafted; (iv) it will, and shall use its best
efforts to ensure that Pharmacare (a) fully complies with all terms and
conditions of the Janssen Agreements, and (b) otherwise maintains the Janssen
Agreements in full force and effect for the entire duration of their respective
terms; and (v) as contemplated in the Janssen Letter Agreement, in the event
Shimoda's rights from Janssen to grant the licenses hereunder are terminated or
altered, Shimoda shall use its best efforts to ensure that IDDS is able to enter
into a license agreement with Janssen for such rights upon terms no less
favorable than the terms afforded Shimoda under the Janssen Agreements.

         10.1.2 Set forth on Schedule A is a list of all prior written
publications, oral presentations and any other public disclosure of the Patent
Rights and/or information covered by Know-How relating to the Shimoda Rights.
Other than as set forth on Schedule A, the Licensed Rights have been kept
confidential by Shimoda and have not been disclosed to any third parties other
than pursuant to a valid and binding confidentiality agreement.

     10.2 By The Farmarc Companies.

                                       27
<PAGE>

                                                                  EXECUTION COPY

          10.2.1 The Farmarc Companies represent and warrant to IDDS that (i)
Farmarc has the full power and authority to enter into this Agreement and to
grant to IDDS the rights granted herein; (ii) Farmarc has all right, title, and
interest in and to the Farmarc Rights, including exclusive, absolute,
irrevocable right, title and interest thereto, free and clear of all liens,
charges, encumbrances or other restrictions or limitations of any kind
whatsoever; and (iii) there are no third parry government or other consents
which are or may be required for IDDS to exercise the rights granted to it by
Farmarc herein, or other licenses, options, restrictions, liens, rights of third
parties, disputes, royalty obligations, proceedings or claims (a) relating to,
affecting, or limiting its rights or the rights granted by Farmarc to IDDS under
this Agreement, or (b) which may lead to a claim of infringement or invalidity
regarding, any part or all of the Farmarc Rights and their use as contemplated
in the underlying patent applications as presently drafted.

          10.2.2 Set forth on Schedule A is a list of all prior written
publications, oral presentations and any other public disclosure of the Patent
Rights and/or information covered by Know-How relating to the Farmarc Rights.
Other than as set forth on Schedule A, the Licensed Rights have been kept
confidential by Farmarc and have not been disclosed to any third parties other
than pursuant to a valid and binding confidentiality agreement.

     10.3 Except as specifically set forth herein, Shimoda and Farmarc, by this
License Agreement, make no representations or warranties as to the validity
and/or breadth of the inventions contained in the Patent Rights and IDDS so
acknowledges.

     10.4 EXCEPT AS MAY BE EXPRESSLY PROVIDED HEREIN, SHIMODA AND FARMARC DO
NOT MAKE, AND EXPRESSLY DISCLAIM, ANY WARRANTIES,

                                       28
<PAGE>

                                                                  EXECUTION COPY

EITHER EXPRESS OR IMPIED, ORAL OR WRITTEN, AS TO ANY MATTER WHATSOEVER,
INCLUDING MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

     10.5 EXCEPT IN CONNCTION WITH THE INDEMNITIES SET FORTH HEREIN OR IN
CONNECTION WITH A BREACH OF THE PARTIES' CONFIDENTIALITY OBLIGATIONS HEREIN, NO
PARTY WILL BE RESPONSIBLE FOR ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL, OR
SPECIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFIT, ARISING PROM THE
DEFAULT OR BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT.

                             ARTICLE 11 - INDEMNITIES

     11.1 By IDDS. IDDS hereby agrees to defend, indemnify and hold Shimoda, its
directors, officers, Affiliates, employees, agents, successors and assigns
harmless from and against all losses, liability, demands, damages, including
without limitation, expenses or losses including death, personal injury, illness
or property damage arising directly or indirectly: (a) out of use by IDDS, its
Affiliates or its transferees of inventions licensed or information furnished
under this Agreement or (b) provided that the Patent Rights are valid and
enforceable and do not infringe any third party rights, out of any use, sale or
other disposition by IDDS or its transferees of Patent Rights, Licensed Products
or Licensed Processes, in each case which are not the result of Shimoda's
negligence or willful misconduct.

     11.2 By the Shimoda Group. The Shimoda Group hereby agrees (i) to defend,
indemnify and hold IDDS, its directors, officers, Affiliates, employees, agents,
successors and assigns harmless from and against all losses, liability, demands,
damages, including without

                                       29
<PAGE>

                                                                  EXECUTION COPY

limitation, expenses or losses including death, personal injury, illness or
property damage arising out of or relating to a breach of its covenants,
representations and warranties set forth herein; and (ii) to defend, indemnify
and hold IDDS, its directors, officers, Affiliates, employees, agents,
successors and assigns harmless from and against all losses, liability, demands,
damages, including without limitation, expenses or losses including death,
personal injury, illness or property damage arising out of or relating to a
breach by the Farmarc Companies of its representations, warranties and covenants
herein.

     11.3 The foregoing indemnities shall be subject to the indemnified party
providing prompt notice to the indemnifying party of any claim hereunder, and
the indemnifying party's right to control the defense of such claim or action.
Any of the indemnified parties shall be permitted to participate in such defense
at its sole cost and expense.

                             ARTICLE 12 - ASSIGNMENT

         This Agreement shall be binding on the parties and their respective
successors in interest and assigns. Neither party shall have the power to assign
this Agreement without the prior written consent of the other party, which
consent shall not be unreasonably withheld, unless such assignment is due the
merger, acquisition, change of control or other corporate reorganization of that
party, provided, however, that such assignee assumes in writing the liabilities.
obligations and responsibilities of the assigning party. Each party shall notify
the other party in writing of such assignment.

                    ARTICLE 13 - PAYMENT OF FEES AND EXPENSES

         Each party shall be responsible for its own expenses relating to the
preparation and consummation of this Agreement and the agreements and
transactions contemplated hereby.

                                       30
<PAGE>
                                                                  EXECUTION COPY

                   ARTICLE 14 - USE OF NAMES AND PUBLICATION

         Nothing contained in this Agreement shall be construed as granting any
right to any party to use in advertising, publicity, or other promotional
activities any name, trade name, trademark, or other designation of any other
party or any of its units (including contraction, abbreviation or simulation of
any of the foregoing) without the prior written consent of such party; provided,
however, that each of the parties hereto acknowledges and agrees that IDDS may
use the name of such party in various documents used by IDDS for capital raising
and financing without such prior written consent where the use of such names may
be required by law.

                      ARTICLE 15 - INDEPENDENT CONTRACTORS

         Nothing herein shall be deemed to establish a relationship of principal
and agent between any of the parties hereto, nor any of their agents or
employees for any purpose whatsoever. This Agreement shall not be construed as
creating a partnership between Shimoda and IDDS, or as creating any other form
of legal association or arrangement which would impose liability upon one party
for the act or failure to act of any other party.

             ARTICLE 16 - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

         Any payment, notice or other communication required or permitted to be
given pursuant to this Agreement shall be in writing and sent by certified first
class mail, postage prepaid, by hand delivery or by facsimile if confirmed
electronically, which in each case shall be effective upon receipt, at the
addresses below or as otherwise designated by written notice given to the other
party:

                                       31
<PAGE>

                                                                  EXECUTION COPY

In the case of Shimoda:

Dr. Lawrence J. Penkler
Managing Director
Shimoda Biotech (Proprietary) Ltd.
152 Cape Road
Mill Park
PO Box 27421
Green Acres 6057
Port Elizabeth, South Africa
Facsimile: 2741-373-6083

In the case of IDDS:

Dr. Leonard Firestone
Chief Executive Officer
Innovative Drug Delivery Systems, Inc.
787 Seventh Avenue, 48th Floor
New York, NY 10019
Facsimile: (212)554-4554

With a copy to:

Brobeck, Phleger & Harrison LLP
1633 Broadway, 47th Floor
New York, New York 10019
Facsimile: (212) 586-7878
Attention: Daryn A. Grossman, Esq.

In the case of Farmarc N.A. N.V.:

Ms Marguerite de Rooy
Farmarc N.A. N.V. (Netherlands Antilles)
62 De Ruyterkade
Curacao, Netherlands Antilles
Facsimile: 599-9-732-2500

With a copy to:

Mr. Darren Shur
Peregrine Corporate Advisory Services (Pty) Ltd
6A Sandown Valley Crescent
Sandown, 2196
Sandton, South Africa
Facsimile: 2711-722-7445

                                       32
<PAGE>

                                                                  EXECUTION COPY

In the case of Farmarc:

Anne-Marie Kuijpers
Farmarc Nederland B.V.
Strawinskylaan 1725
1077 XX Amsterdam, The Netherlands
Facsimile: 31-20-664-7557

With a copy to;

Mr. Darren Shur
Peregrine Corporate Advisory Services (Pty) Ltd
6A Sandown Valley Crescent
Sandown, 2196
Sandton, South Africa
Facsimile 2711-722-7445

                          ARTICLE 17 - CONFIDENTIALITY

     17.1 Each of the parties agrees that all business, technical and financial
information, and information it obtains from any other party which is
confidential or proprietary in nature is the Confidential Information of the
disclosing party. Except as expressly and unambiguously allowed herein, each
receiving party will hold in confidence, use such Confidential Information only
in furtherance of its obligations hereunder and not disclose to any third party
any Confidential Information of any other party and shall similarly bind its
employees and agents in writing. A receiving party shall not be obligated under
this Paragraph 17 with respect to information such receiving party can document
is:

          17.1.1 received at any time from a third party lawfully in possession
of same and having the right to disclose same.

          17.1.2 as of the date of this Agreement, in the public domain, or
subsequently enters the public domain through no fault of the receiving party.

                                       33
<PAGE>

                                                                  EXECUTION COPY

          17.1.3 independently developed by the receiving party as demonstrated
by written evidence without reference to information disclosed to the receiving
party by the disclosing party.

          17.1.4 disclosed pursuant to the prior written approval of the
disclosing party.

          17.1.5 required to be disclosed pursuant to law or legal process
(including, without limitation, to a governmental authority) provided, in the
case of disclosure pursuant to legal process, reasonable notice of the impending
disclosure is provided to the disclosing party and such party has agreed to such
disclosure in writing or has exhausted its right to contest such disclosure.

          The parties specifically agree that the terms of this Agreement shall
be considered "Confidential Information" for the purposes of this Article 17.

                      ARTICLE 18 - MISCELLANEOUS PROVISIONS

     18.1 This Agreement shall be construed, governed, interpreted and
applied in accordance with the laws of the State of New York, without regard to
principles of conflicts of laws.

     18.2 The parties hereto acknowledge that this Agreement, its schedules
and exhibits, sets forth the entire agreement and understanding of the parties
hereto as to the subject matter hereof, and shall not be subject to any change
or modification except by the execution of a written instrument subscribed to by
the parties hereto.

     18.3 The provisions of this Agreement are severable, and in the event
that any provision of this License Agreement shall be determined to be invalid
or unenforceable under

                                       34
<PAGE>

                                                                  EXECUTION COPY

any controlling body of law, such invalidity or unenforceability shall not in
any way affect the validity or enforceability of the remaining provisions
hereof.

     18.4 The failure of any party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a
waiver of that right or excuse a similar subsequent failure to perform any such
term or condition by the other party.

     18.3 The headings of the several articles are inserted for convenience of
reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement.

     18.6 This Agreement will not be binding upon the parties until it has been
signed below on behalf of each of the parties, in which event, it shall be
effective as of the date recited on page one.

     18.7 This Agreement embodies the entire understanding of the parties and
shall supersede all previous communications, representations or understandings,
either oral or written, between the panics relating to the subject matter
hereof.

     18.8 Each of the parties hereto shall be excused from any breach of this
Agreement which is proximately caused by governmental regulation, act of war,
strike, act of God or other similar circumstance normally deemed outside the
control of the parties.

                REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

                                       35
<PAGE>

                                                                  EXECUTION COPY

         IN WITNESS WHEREOF, the parties hereto have executed this License
Agreement, in triplicate by proper persons thereunto duly authorized.

INNOVATIVE DRUG DELIVERY                           SHIMODA BIOTECH (PROPRIETARY)
SYSTEMS, INC.                                      LTD.

By: /s/ Leonard Firestone                          By:

Name: Leonard Firestone                            Name:

Title: Chief Executive Officer                     Title:

Date: 12/14/2001                                   Date:

FARMARC NEDERLAND B.V.                             FARMARC N.A. N.V.

By:                                                By:

Name:                                              Name:

Title:                                             Title:

Date:                                              Date:

                                       36
<PAGE>

                                                                  EXECUTION COPY

         IN WITNESS WHEREOF, the parties hereto have executed this License
Agreement, in triplicate by proper persons thereunto duly authorized.

INNOVATIVE DRUG DELIVERY                           SHIMODA BIOTECH (PROPRIETARY)
SYSTEMS, INC.                                      LTD.

By:                                                By: /s/ D Shur

Name:                                              Name: D.L. Shur

Title:                                             Title: Director

Date:                                              Date: 14/12/2001

FARMARC NEDERLAND B.V.                             FARMARC N.A. N.V.

By:  /s/ MG Attridge                               By:  MG Attridge

Name: MG Attridge                                  Name: MG Attridge

Title: Director                                    Title: Nominee

Date: 14/12/01                                     Date: 14/12/01

                                       37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]